# Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery

> **NCT07515391** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Dasman Diabetes Institute** · enrollment: 30 (estimated)

## Conditions studied

- Bariatric Surgery Candidate
- Type2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin 10 MG

## Key facts

- **NCT ID:** NCT07515391
- **Lead sponsor:** Dasman Diabetes Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2019-10-22
- **Primary completion:** 2021-05-01
- **Final completion:** 2026-10-22
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07515391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07515391, "Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07515391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*